Entry Point Capital, LLC Taysha Gene Therapies, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 61,495 shares of TSHA stock, worth $99,006. This represents 0.05% of its overall portfolio holdings.
Number of Shares
61,495
Previous 27,027
127.53%
Holding current value
$99,006
Previous $54,000
96.3%
% of portfolio
0.05%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding TSHA
# of Institutions
130Shares Held
151MCall Options Held
48KPut Options Held
7.8K-
Avoro Capital Advisors LLC New York, NY20MShares$32.2 Million0.5% of portfolio
-
Morgan Stanley New York, NY17.6MShares$28.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$18.9 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$17.5 Million0.3% of portfolio
-
Octagon Capital Advisors LP New York, NY10.5MShares$16.8 Million4.03% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $77.9M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...